autologous

February 7, 2012

Stem Cell Competition Heating Up

August 23, 2010 By MD Becker Partners 2 Comments

Stem cell

According to the National Institutes of Health’s [NIH] stem cell primer, stem cells have the ability to develop into many different cell types in the body during early life and growth. In many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each [...]

Filed Under: Articles Tagged With: Aastrom Biosciences, ALD-301, Aldagen, allogeneic, ALS, amyotrophic lateral sclerosis, ASTM, Athersys, ATHX, autologous, BCLI, BrainStorm Cell Therapeutics, cardiovascular, CELG, Celgene, Celution, central nervous system, CNS, Critical limb ischemia, Crohn’s disease, CUR, Cytori Therapeutics, CYTX, Dendreon, DNDN, gastrointestinal, GERN, Geron, myocardial infarction, Neuralstem, NurOwn, OSIR, Osiris Therapeutics, PDA-001, Pluristem, PLX-PAD, Prochymal, PSTI, STEM, stem cells, StemCells

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL